How much funding has Altesa Biosciences raised?

Altesa Biosciences has raised $114.0M in total funding, most recently a Series B round.

Who are Altesa Biosciences's investors?

Altesa Biosciences's investors include Forbion Capital Partners, Pitango Growth, Sanofi Ventures, Atlantic Capital Group, Medicxi.

Where is Altesa Biosciences headquartered?

Altesa Biosciences is headquartered in College Park, Georgia, United States.

What industry is Altesa Biosciences in?

Altesa Biosciences operates in Biotech, Healthcare.

How many employees does Altesa Biosciences have?

Altesa Biosciences has 1-10 employees.

Altesa Biosciences

Protecting Lungs. Improving Lives.

College Park, United States · $114.0M raised

Biotech

Healthcare

Headquarters: College Park, Georgia
Employees: 1–10
Business Model: B2B
Website: altesabio.com

Total Funding: $114.0M
Last Round: $75.0M Series BFeb 2026
Rounds: 3

About

Altesa BioSciences is a clinical-stage pharmaceutical company focused on developing antiviral therapies to protect people with chronic lung diseases from life-threatening respiratory virus infections. The company's primary program targets rhinovirus — the most common respiratory pathogen and the leading trigger of acute exacerbations in COPD and asthma patients — with an oral antiviral medicine (vapendavir) intended to prevent hospitalization and long-term lung function decline. Altesa's pipeline addresses a significant unmet need, as COPD affects 18.6 million Americans and generates an estimated $6.24 trillion in direct US medical costs between 2025 and 2050.

Summary

Altesa Biosciences is a Biotech company based in College Park, United States. It has raised $114.0M in total across 3 rounds, most recently a $75.0M Series B round in Feb 2026. Investors include Forbion Capital Partners, Pitango Growth and Sanofi Ventures.